SCYNEXIS INC
SCYX · Pharmaceutical Preparations · 79.4M shares · +23%/yr ↑ shares · EDGAR filings ↗
Grade
C55Antifungal company with an approved, GSK-licensed product (ibrexafungerp) and adequate cash, but its lead next-gen asset is only Phase 1 and a key Phase 3 (MARIO) was wound down.
Strengths
- Approved first-in-class product generating GSK/Hansoh/R-Pharm royalty potential; positive VANISH Phase 3 VVC data
- Cash $56M, current ratio 7.0 (70th pct); one-off $24.8M GSK payment bolstered 2025
Risks
- 94.8th-pct revenue growth is a non-recurring milestone/catch-up artifact, not organic
- Lead SCY-247 only completing Phase 1; MARIO termination and continuing operating losses (net margin -0.42)
Notable findings
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-78.0%
Net margin
-41.8%
Return on equity
-17.4%
Return on assets
-14.6%
Revenue growth (QoQ)
-100.0%
Current ratio
7.0×
Tangible book value
$49M
Cash & investments
$56M
Stock comp / revenue
13.8%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | Angulo Gonzalez David | Buy | 109K | — |
| 2026-01-29 | Macleod ivor | Grant | 130K | — |
| 2026-01-29 | Angulo Gonzalez David | Grant | 391K | — |
| 2026-01-29 | Sukenick Scott | Grant | 130K | — |
| 2025-10-17 | Angulo Gonzalez David | Grant | 32K | $0.76 |
| 2025-06-26 | ANIDO ARMANDO | Grant | 23K | — |
| 2025-06-26 | HANHAM ANN | Grant | 23K | — |
| 2025-06-26 | Tinmouth Brian Philippe | Grant | 23K | — |
| 2025-06-26 | Macdonald Guy | Grant | 23K | — |
| 2025-06-26 | HASTINGS DAVID C | Grant | 23K | — |
| 2025-06-26 | GILMAN STEVEN C | Grant | 23K | — |
| 2025-04-09 | Angulo Gonzalez David | Grant | 23K | $0.84 |
| 2025-03-20 | Angulo Gonzalez David | Grant | 14K | $1.05 |
| 2025-03-19 | Angulo Gonzalez David | Grant | 5.0K | $1.07 |
| 2025-01-23 | Sukenick Scott | Grant | 93K | — |
| 2025-01-23 | Macleod ivor | Grant | 93K | — |
| 2025-01-23 | Angulo Gonzalez David | Grant | 263K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05908682 ↗ | Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes Vulvovaginal Candidiasis, Candida Infection | — | Recruiting | 2029-10-31 |
| NCT05178862 ↗ | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole Candidiasis, Invasive, Candidemia | PHASE3 | Terminated | 2025-11-07 |
| NCT06954493 ↗ | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Vulvovaginal Candidiasis, Candida Infection | PHASE1 | Completed | 2023-11-01 |
| NCT03059992 ↗ | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Invasive Candidiasis, Mucocutaneous Candidiasis | PHASE3 | Completed | 2023-08-25 |
| NCT05399641 ↗ | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Vulvovaginal Candidiasis | PHASE3 | Completed | 2023-05-16 |
| NCT03363841 ↗ | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) Candidiasis, Invasive, Candidemia | PHASE3 | Completed | 2023-04-14 |
| NCT03672292 ↗ | Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis Invasive Pulmonary Aspergillosis | PHASE2 | Terminated | 2023-03-27 |
| NCT05668429 ↗ | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects Fungal Disease | PHASE1 | Completed | 2023-01-28 |
| NCT04029116 ↗ | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Recurrent Vulvovaginal Candidiasis | PHASE3 | Completed | 2021-09-01 |
| NCT04307082 ↗ | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects Fungal Infection | PHASE1 | Completed | 2020-05-29 |
| NCT03987620 ↗ | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Candida Vulvovaginitis | PHASE3 | Completed | 2020-03-29 |
| NCT04092725 ↗ | Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Pharmacokinetics | PHASE1 | Completed | 2020-01-03 |
| NCT04092751 ↗ | Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects Pharmacokinetics | PHASE1 | Completed | 2019-12-20 |
| NCT03734991 ↗ | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) Candida Vulvovaginitis | PHASE3 | Completed | 2019-08-21 |
| NCT03253094 ↗ | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Candida Vulvovaginitis | PHASE2 | Completed | 2018-05-04 |
| NCT02679456 ↗ | Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Vulvovaginal Candidiasis | PHASE2 | Completed | 2016-08-05 |
| NCT02244606 ↗ | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Mycoses, Candidiasis, Invasive | PHASE2 | Completed | 2016-06-01 |
| NCT01265511 ↗ | Study of SCY-635, Pegasys and Copegus in Hepatitis C Hepatitis C Infection | PHASE2 | Completed | 2011-10-01 |
| NCT01290965 ↗ | Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients Chronic Hepatitis C | PHASE1 | Completed | 2008-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (3)
- GlaxoSmithKline (GSK)
- Hansoh
- R-Pharm
Suppliers (1)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-26 | 5.03Shareholder voteOtherExhibits | filing ↗ |
| 2026-05-29 | 5.03Exhibits | filing ↗ |
| 2026-05-22 | Shareholder voteOther | filing ↗ |
| 2026-04-20 | Exec/director change | filing ↗ |
| 2026-03-31 | Reg FDExhibits | filing ↗ |
| 2026-03-31 | Material agreement3.02Reg FDOtherExhibits | filing ↗ |
| 2026-03-31 | Material agreementAcquisition/dispositionReg FDExhibits | filing ↗ |
| 2025-10-15 | Material agreement | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-26 | 2026-06-25 | 0001178253-26-000021 ↗ |
| 8-K | 2026-05-29 | 2026-05-28 | 0001178253-26-000017 ↗ |
| 8-K | 2026-05-22 | 2026-05-19 | 0001178253-26-000014 ↗ |
| 10-Q | 2026-05-11 | 2026-03-31 | 0001178253-26-000011 ↗ |
| 8-K | 2026-04-20 | 2026-04-16 | 0001178253-26-000009 ↗ |
| 8-K | 2026-03-31 | 2026-03-30 | 0001193125-26-133250 ↗ |
| 8-K | 2026-03-31 | 2026-03-30 | 0001193125-26-133259 ↗ |
| 8-K | 2026-03-31 | 2026-03-31 | 0001193125-26-134476 ↗ |
| 10-K | 2026-03-04 | 2025-12-31 | 0001178253-26-000007 ↗ |
| 10-Q | 2025-11-05 | 2025-09-30 | 0001178253-25-000010 ↗ |
| 8-K | 2025-10-15 | 2025-10-14 | 0001178253-25-000006 ↗ |
| 10-Q | 2025-08-13 | 2025-06-30 | 0000950170-25-107985 ↗ |